Get the Stockscreener App
85.78
1.80%
1.52
After Hours:
85.81
0.03
+0.03%
Edwards Lifesciences Corp stock is traded at $85.78, with a volume of 6.22M.
It is up +1.80% in the last 24 hours and up +11.33% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$84.26
Open:
$83.99
24h Volume:
6.22M
Relative Volume:
1.52
Market Cap:
$49.82B
Revenue:
$6.07B
Net Income/Loss:
$1.06B
P/E Ratio:
47.49
EPS:
1.8063
Net Cash Flow:
$1.34B
1W Performance:
+0.59%
1M Performance:
+11.33%
6M Performance:
+9.58%
1Y Performance:
+25.17%
1-Day Range:
$82.88
$86.38
1-Week Range:
$80.50
$86.38
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.78 | 48.94B | 6.07B | 1.06B | 1.34B | 1.8063 |
|
ABT
Abbott Laboratories
|
110.55 | 195.75B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
358.65 | 140.03B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.89 | 117.27B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.96 | 106.69B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences jumps 3.21% with $400M traded, placing 368th in volume; revenue growth exceeds earnings shortfall - Bitget
Is Edwards Lifesciences Stock Outperforming the S&P 500? - Barchart.com
Niranjan Pai joins Edwards Lifesciences as Director-Government Affairs - Exchange4Media
Inceptionr LLC Makes New $1.61 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Rathbones Group PLC Has $6.84 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Rhenman & Partners Asset Management AB Has $12.05 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Blair William & Co. IL Has $28.96 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
How Edwards Lifesciences Corporation stock performs during Fed tightening cyclesJuly 2025 Weekly Recap & Consistent Profit Alerts - Naître et grandir
Edwards Lifesciences Corp (EW) Trading Down 3.41% on Mar 6 - GuruFocus
Fisher Asset Management LLC Cuts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences Corporation $EW Shares Acquired by Elo Mutual Pension Insurance Co - MarketBeat
Edwards Lifesciences Corp (EW) Stock Price Down 3.76% on Mar 3 - GuruFocus
Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook - simplywall.st
Edwards Lifesciences (NYSE:EW) VP Sells $974,446.20 in Stock - MarketBeat
Edwards Lifesciences Corp Officer Sells Shares - TradingView
Edwards Lifesciences at TD Cowen Conference: Strategic Growth and Innovation - Investing.com
Why Investors Are Eyeing Edwards Lifesciences Corp (EW): The Key - GuruFocus
Intech Investment Management LLC Increases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Is Up 8.4% After SAPIEN M3 FDA Win And FTC SetbackHas The Bull Case Changed? - simplywall.st
Huntington National Bank Sells 14,023 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Erste Asset Management GmbH Lowers Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Hits Day High with Strong 3% Intraday Surge - Markets Mojo
TD Asset Management Inc Sells 12,562 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Insider Sold Shares Worth $2,012,076, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Bobo sells $2m in stock - Investing.com
Edwards Lifesciences (NYSE: EW) VP sells 24,000 common shares - Stock Titan
Edwards Lifesciences Corp Officer Sells 24,000 Shares - TradingView
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Edwards Lifesciences at Citi’s MedTech Day: Optimism in Growth Strategies - Investing.com
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Edwards Lifesciences plans to reach 2M underserved heart patients by 2030 - Stock Titan
How The Edwards Lifesciences (EW) Investment Story Is Shifting After Mixed Analyst Revisions - Yahoo Finance
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences Hits Day High with Strong 3.28% Intraday Surge - Markets Mojo
Edwards Lifesciences Hits Day High with Strong 3.33% Intraday Surge - Markets Mojo
Edwards Lifesciences Opens with 3.2% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Edwards Lifesciences Stock Climbs 1.21% on Stronger Revenue, $0.35 Billion Trading Volume Ranks 387th for the Day - Bitget
Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed - Yahoo Finance
NEW SURVEY BY EDWARDS LIFESCIENCES UNCOVERS JUST HOW MUCH AMERICANS KNOW ABOUT THEIR HEART HEALTH - Yahoo Finance
Daiwa Securities Adjusts Price Target on Edwards Lifesciences to $98 From $99, Maintains Buy Rating - marketscreener.com
Here is Why Edwards Lifesciences Corporation (EW) Looks Attractive - Insider Monkey
Edwards Lifesciences (EW) SVP reports 176-share tax-withholding disposition - Stock Titan
Edwards Lifesciences Corp (EW)'s Winning Formula: Financial Metr - GuruFocus
Equitable Trust Co. Sells 15,075 Shares of Edwards Lifesciences Corporation $EW - Defense World
Cardiac Valve Market 20262035 Major Key Players: Edwards - openPR.com
Will Edwards Lifesciences Corporation stock deliver long term returnsTrade Analysis Summary & Proven Capital Preservation Methods - mfd.ru
Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario - TIKR.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):